Jack Wallace
Stock Analyst at Guggenheim
(3.14)
# 1,156
Out of 5,114 analysts
18
Total ratings
57.89%
Success rate
273.86%
Average return
Main Sectors:
Stocks Rated by Jack Wallace
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Buy | $233 → $249 | $221.86 | +12.23% | 4 | Oct 1, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $15 → $17 | $35.56 | -52.19% | 4 | Feb 27, 2024 | |
| HCAT Health Catalyst | Upgrades: Buy | $14 | $2.35 | +495.74% | 3 | Jan 26, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $253 → $220 | $220.69 | -0.31% | 1 | Nov 3, 2023 | |
| PHR Phreesia | Maintains: Buy | $35 → $40 | $16.55 | +141.69% | 5 | Mar 29, 2023 | |
| AMWL American Well | Reiterates: Buy | $100 | $4.66 | +2,045.92% | 1 | Mar 15, 2023 |
Veeva Systems
Oct 1, 2024
Maintains: Buy
Price Target: $233 → $249
Current: $221.86
Upside: +12.23%
Hims & Hers Health
Feb 27, 2024
Maintains: Buy
Price Target: $15 → $17
Current: $35.56
Upside: -52.19%
Health Catalyst
Jan 26, 2024
Upgrades: Buy
Price Target: $14
Current: $2.35
Upside: +495.74%
IQVIA Holdings
Nov 3, 2023
Maintains: Buy
Price Target: $253 → $220
Current: $220.69
Upside: -0.31%
Phreesia
Mar 29, 2023
Maintains: Buy
Price Target: $35 → $40
Current: $16.55
Upside: +141.69%
American Well
Mar 15, 2023
Reiterates: Buy
Price Target: $100
Current: $4.66
Upside: +2,045.92%